For patients without insurance coverage for weight management medications, or with high deductibles, compounded tirzepatide offered a pathway to treatment that branded versions priced out of reach
Cosmos Study November 13, 2025 Dual-Team Study Team A:Kersten Bartelt, RNDan GreerEmily Higgs Team B:Louis Kazaglis, MDTed Stamp Key Findings Among patients with polycystic ovary syndrome (PCOS), the median one-year weight change was an 11.5% loss for those treated with a GLP-1, compared to a 1.9% loss among those treated with metformin
We further demonstrate that in female mice, sensitivity to the aversive properties of these drugs is estrous cycle-dependent, with responsiveness being amplified during proestrus, when circulating estrogen levels peak, and minimized during diestrus, when estrogen levels are low
Wegovy, containing semaglutide, has been approved for obesity treatment and has shown significant efficacy in clinical trials